U.S. Markets closed

Karolinska Development AB (publ) (0P3C.L)

LSE - LSE Delayed Price. Currency in SEK
Add to watchlist
2.6177-0.0100 (-0.38%)
At close: 05:43PM BST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.6277
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's Range2.6177 - 2.6177
52 Week Range2.6177 - 2.6177
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)0.23
PE Ratio (TTM)1.67
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Karolinska Development’s portfolio company Umecrine Cognition recruits Anders Karlsson as the new CEO

    STOCKHOLM, SWEDEN – August 10, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the Board of Directors of the portfolio company Umecrine Cognition has recruited Anders Karlsson as the new CEO. He succeeds Magnus Doverskog, who moves on to a position as Chief Scientific Officer in the company. The recruitment aims to strengthen and broaden the management team with additional competence in business development and commercialization for the next phase in the company’s d

  • GlobeNewswire

    Karolinska Developments portfolio company Promimic and Danco Medical form a joint venture for the US-market

    STOCKHOLM, SWEDEN, July 22 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic and the US-based company Danco Medical form a joint venture for the Processing of Medical Implants in the US market. The strategic initiative is expected to have a major impact on Promimic’s growth and profitability as early as next year. Danco Medical has been Promimic’s partner in the US since 2016 and the companies are now deepening their collaboration furthe

  • GlobeNewswire

    Karolinska Development expands its portfolio following an investment in PharmNovo

    STOCKHOLM, SWEDEN, July 4, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) has completed a previously announced investment in PharmNovo, thereby including it among its portfolio companies. As of July 4, Karolinska Development’s investment portfolio consists of ten companies. Karolinska Development has invested SEK 20 million in PharmNovo, within the framework of a new share issue led by Sciety that in total contributed approximately SEK 67 million to the company. PharmNovo is developing